# Cardiff Oncology, Inc. (CRDF)

> Source: Nexqual · https://nexqual.com/CRDF · data as of 2026-10-15 20:00 UTC · cite as "Nexqual, Cardiff Oncology, Inc. (CRDF), nexqual.com/CRDF" · informational, not investment advice.

**Price:** USD 0.97 (-0.25% on the day) · last close of Oct 15, 2026; US market closed, not a live price. Prev close 0.97 · day 0.95–1 · 52w 0.76–3.31 · market cap $75.5M · NCM

## Key facts
- Analysts: Buy (mean 2.33 on a 1–5 scale) (6 analysts), mean target USD 5.81 (range 1.2–12).
- Total return with dividends: 1Y -56.7% vs S&P 500 +18.1%; 5Y -84.8% vs S&P 500 +85.1%.
- Next earnings: 2026-11-12, EPS estimate USD -0.13, revenue estimate $86K.

## Analysts
Consensus Buy (mean 2.33 on a 1–5 scale), 6 analysts; mean target USD 5.81 (low 1.2, high 12).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-15 | HC Wainwright & Co. | Upgrade | Neutral → Buy | $9 |
| 2026-08-12 | William Blair | Downgrade | Outperform → Market Perform |  |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-16) | 5Y (from 2021-10-11) |
|---|---|---|
| Total return | -56.7% | -84.8% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -56.8% | -31.4% |
| Volatility (annualized) | 91.4% | 95.6% |
| Max drawdown | -74.8% (Jan 2026→Jul 2026) | -87.9% (Jan 2022→Jul 2026) |

## Peers (Biotechnology)
RYTM (Rhythm Pharmaceuticals, Inc.) USD 87.97 +1.57% · BLTE (Belite Bio, Inc) USD 152.62 +0.49% · IOVA (Iovance Biotherapeutics, Inc.) USD 14.72 +1.52% · PRAX (Praxis Precision Medicines, Inc) USD 248.24 +2.01% · IONS (Ionis Pharmaceuticals, Inc.) USD 44.12 +4.11% · SYRE (Spyre Therapeutics, Inc.) USD 80.1 -0.44%

## More
Full page: https://nexqual.com/CRDF · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt